908 Devices (NASDAQ:MASS) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• 908 Devices beat quarterly expectations: It reported a loss of $0.11 per share versus the expected $0.15 loss, while revenue of $18.95 million topped estimates of $18.31 million.
• Revenue growth and outlook strengthened: Q3 revenue rose 35% year over year to a record level, and the company raised the low end of its 2026 revenue forecast to $68.5 million, projecting 22%–25% annual growth.
• Shares fell despite the results: The stock dropped 14.2% to $9.88 in Tuesday trading; management cited execution-dependent opportunities and continued operating losses, with $99.1 million in cash and no debt at quarter-end.

908 Devices (NASDAQ:MASS - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04, FiscalAI reports. The firm had revenue of $18.95 million for the quarter, compared to analysts' expectations of $18.31 million. 908 Devices had a negative return on equity of 12.54% and a negative net margin of 56.96%.

Here are the key takeaways from 908 Devices' conference call:

• Revenue growth accelerated and guidance increased: Q3 revenue rose 35% year over year to a record $19 million, and the company raised the low end of its 2026 revenue outlook to $68.5 million–$70 million, implying 22%–25% annual growth.
• Device adoption broadened, including internationally: 908 Devices shipped a record 300-plus devices, bringing its installed base to about 4,400; international customers accounted for 40% of Q3 revenue, supported by ProtectIR government wins and other platform demand.
• NIRLab showed early commercial traction: The company sold about 100 devices in the quarter, while platform scans surpassed 1 million cumulatively. Management sees subscriptions and broader connected services as a potential source of recurring revenue, though the business is still developing.
• Profitability improved modestly, while future growth depends on execution: Adjusted EBITDA loss was $1.7 million, and the company ended Q3 with $99.1 million in cash and no debt. Management cited the next-generation MX908 and potential 2027 AVCAD orders as growth drivers, but AVCAD revenue is excluded from 2026 guidance and reaching the upper end of the outlook depends on closing key Q4 opportunities.

908 Devices Trading Down 14.2%

908 Devices stock traded down $1.63 during trading on Tuesday, hitting $9.88. The company had a trading volume of 213,061 shares, compared to its average volume of 337,247. The stock has a market cap of $408.38 million, a price-to-earnings ratio of -10.40 and a beta of 0.66. 908 Devices has a 1-year low of $5.03 and a 1-year high of $13.35. The company's 50 day simple moving average is $11.21 and its 200-day simple moving average is $8.50.

Insiders Place Their Bets

In other news, CFO Joseph H. Iv Griffith sold 11,459 shares of 908 Devices stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $10.95, for a total value of $125,476.05. Following the completion of the sale, the chief financial officer directly owned 121,497 shares of the company's stock, valued at approximately $1,330,392.15. The trade was a 8.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 21,399 shares of 908 Devices stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $10.11, for a total value of $216,343.89. Following the completion of the sale, the senior vice president directly owned 57,784 shares of the company's stock, valued at $584,196.24. The trade was a 27.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 134,115 shares of company stock worth $1,473,296 over the last ninety days. Corporate insiders own 28.20% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on MASS shares. Wall Street Zen lowered 908 Devices from a "buy" rating to a "hold" rating in a research note on Saturday, September 12th. Roth Capital raised their price objective on 908 Devices from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research report on Wednesday, November 4th. Canaccord Genuity Group initiated coverage on shares of 908 Devices in a report on Thursday, September 10th. They issued a "buy" rating and a $13.50 price objective on the stock. Finally, Stifel Nicolaus upped their target price on shares of 908 Devices from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $12.83.

About 908 Devices

908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions.

The company's product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.